Repare Therapeutics (NASDAQ:RPTX - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.17, Zacks reports. The firm had revenue of $0.25 million for the quarter, compared to analyst estimates of $2.50 million.
Repare Therapeutics Stock Performance
RPTX stock traded down $0.03 during trading on Thursday, reaching $1.56. 95,926 shares of the company were exchanged, compared to its average volume of 145,919. The company has a market cap of $67.02 million, a P/E ratio of -0.60 and a beta of 0.93. Repare Therapeutics has a 52-week low of $0.89 and a 52-week high of $4.07. The stock's 50 day moving average price is $1.48 and its 200 day moving average price is $1.31.
Institutional Trading of Repare Therapeutics
A hedge fund recently raised its stake in Repare Therapeutics stock. Acadian Asset Management LLC lifted its position in shares of Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report) by 35.6% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 640,332 shares of the company's stock after buying an additional 168,230 shares during the period. Acadian Asset Management LLC owned 1.49% of Repare Therapeutics worth $624,000 as of its most recent SEC filing. Institutional investors and hedge funds own 85.09% of the company's stock.
Analyst Ratings Changes
Separately, Wall Street Zen upgraded shares of Repare Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Repare Therapeutics has a consensus rating of "Hold" and an average price target of $4.50.
Read Our Latest Stock Report on Repare Therapeutics
About Repare Therapeutics
(
Get Free Report)
Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.
Read More
Before you consider Repare Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repare Therapeutics wasn't on the list.
While Repare Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
